Stage
No active trials
Next date
None yet
Trials
76 active
84 in total · 83 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Myeloid Leukemia
- Main trialPhase 1
- “This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.”In the company’s words, NCT03790072 on ClinicalTrials.gov
- Other names
- fludarabine · cyclophosphamide
Other drugs for Acute Myeloid Leukemia
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials84
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 26 Mar 2021 | Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) | |
| Phase 3Halted | not given | International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents | |
| Phase 2Authorised | not given | HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements | |
| Phase 3Authorised | not given | A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer | |
| Phase 3Authorised | not given | International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma | |
| Phase 3Authorised | not given | An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy | |
| Phase 2Authorised | not given | "SKYLINE": Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer: A phase II trial | |
| Phase 2Expired | not given | A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy | |
| Phase 3Ended | not given | HOVON 127 BL / SAKK 37/16: Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma | |
| Phase 4Authorised | not given | Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium | |
| Phase 1Authorised | not given | A Phase 1 Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemia | |
| Phase 3Authorised | not given | B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents | |
| Phase 3Authorised | not given | A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation. | |
| Phase 4Authorised | not given | Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trial (UPSIDE) | |
| Phase 2Authorised | not given | Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial (HYPERION) | |
| Phase 2Authorised | not given | Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplastic sensory neuropathy (NESPA). | |
| Phase 1/2Authorised | not given | "FAP-IT" 68Ga-FAPI-46 PET/CT for predicting histological response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer | |
| Phase 4Authorised | not given | Evaluating, clinical and immunological effects of rituximab with cyclophosphamide compared to rituximab alone in AAV patients (The ENDURRANCE-1 Study) | |
| Phase 3Authorised | not given | LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |
| Phase 2Authorised | not given | EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study | |
| Phase 3Authorised | not given | Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820 | |
| Phase 2Authorised | not given | Randomized Phase 2 study testing two conditioning regimen with a single prophylaxis of graft-versus-host disease by cyclophosphamide and methotrexate post-transplant in patients eligible for matched-donor allograft transplantation _ CY-MET-RIC | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 3Authorised | not given | A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML | |
| Phase 3Ended | not given | Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG | |
| Phase 2Authorised | not given | A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation. ALL2418 | |
| Phase 3Authorised | not given | SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. | |
| Phase 1/2Authorised | not given | FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |
| Phase 3Authorised | not given | Randomized Autologous heMatopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis (RAM-MS) | |
| Phase 3Authorised | not given | GERICO14 : Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program | |
| Phase 2Authorised | not given | A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL) | |
| Phase 3Authorised | not given | Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma A randomized, open label, phase III study by Fondazione Italiana Linfomi. | |
| Phase 2Authorised | not given | Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (ABC)-DLBCL at intermediate-high and high risk (IPI ≥2) | |
| Phase 2Authorised | not given | A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation | |
| Phase 2Authorised | not given | Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase ll randomised trial | |
| Phase 3Authorised | not given | Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease : multicentric randomized phase III trial (CATR-PAT) | |
| Phase 2/3Authorised | not given | SIOP Ependymoma Program II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependymoma | |
| Phase 4Authorised | not given | MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL (RESOLVE trial). | |
| Phase 2/3Authorised | not given | ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia | |
| Phase 2/3Authorised | not given | LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis | |
| Phase 2Authorised | not given | FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis : A phase 2 prospective multicentric prospective study | |
| Phase 1/2Ended | not given | Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors | |
| Phase 2/3Authorised | not given | An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition | |
| Phase 2Authorised | not given | PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A REDUCED-INTENSITY REGIMEN BASED ON FLUDARABINE AND MELPHALAN AS CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA. | |
| Phase 2Authorised | not given | PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) ADMINISTERED IN COMBINATION WITH A MYELOABLATIVE REGIMEN BASED ON CYCLOPHOSPHAMIDE AND ETOPOSIDE AS A CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA | |
| Phase 4Authorised | not given | TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer | |
| Phase 2Authorised | not given | RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated | |
| Phase 2Authorised | not given | PELICAN-IPC 2015-016 A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen in HER2-negative inflammatory Breast Cancer | |
| Phase 3Authorised | not given | HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy | |
| Phase 2Authorised | not given | Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease | |
| Phase 2Authorised | not given | Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - The p53 breast cancer trial | |
| Phase 1Authorised | not given | International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma | |
| Phase 2Ended | not given | NO EVIDENCE OF DISEASE ACTIVITY AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE MULTIPLE SCLEROSIS: THE NET-MS STUDY | |
| Phase 3Authorised | not given | International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | |
| Phase 2Authorised | not given | MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors | |
| Phase 2Authorised | not given | "EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up | |
| Phase 2/3Authorised | not given | rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | |
| Phase 3Authorised | not given | Myechild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy | |
| Phase 2Authorised | not given | Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative breast cancer | |
| Phase 3Authorised | not given | STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years | |
| Phase 3Authorised | not given | SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less | |
| Phase 3Authorised | not given | GERICO11_Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial | |
| Phase 3Authorised | not given | Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) | |
| Phase 3Authorised | not given | Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study group. | |
| Phase 3Authorised | not given | Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR | |
| Phase 2Authorised | not given | RemiRit - Personalized immunosuppressive therapy with rituximab in the treatment of ANCA associated vasculitis - a randomized, multicenter clinical trial | |
| Phase 3Authorised | not given | NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years | |
| Phase 2Authorised | not given | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group. The “EUMELEIA” Study | |
| Phase 2/3Authorised | not given | Ruxolitinib for childhood ALL in Poland (Rux-cALL-Pol 2020 trial) - Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. | |
| Phase 2Authorised | not given | Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma. | |
| Phase 2Ended | not given | BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma | |
| Phase 2Authorised | not given | An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours | |
| Phase 2Authorised | not given | Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma | |
| Phase 3Authorised | not given | OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women | |
| Phase 3Authorised | not given | Reduced post-transplant cyclophosphamide dose in patients undergoing haploidentical hematopoietic stem cell transplantation for hematological malignancies: a phase III randomized study (REDUCy) | |
| Phase 2Authorised | not given | Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years) | |
| Phase 3Authorised | not given | NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial | |
| Phase 2Authorised | not given | Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML) | |
| Phase 2Authorised | not given | BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma | |
| Phase 3Authorised | not given | AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia | |
| Phase 3Authorised | not given | The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia | |
| Phase 2Authorised | not given | FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML | |
| Phase 4Authorised | not given | Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026